Drug intelligence / Profile preview

PM 1251

Development stage: Unknown
Lead developer: Phytomyco Research
Modality: Small Molecules

Overview

PM 1251 is a natural product-derived small molecule therapeutic candidate developed by Phytomyco Research. It is currently being evaluated for its anti-inflammatory properties in early-stage clinical development. The compound is part of the company's pharmaceutical pipeline, which focuses on identifying and developing bioactive molecules from natural sources for systemic inflammatory conditions. As of the current reporting, PM 1251 has progressed through animal studies and is undergoing Phase 1 human clinical trials to assess its safety and efficacy.

Beyond the preview

Go deeper on PM 1251.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PM 1251.

Explore the full profile